PERJETA

Reason for request

Clinical Benefit

Substantial

The actual benefit of PERJETA in combination with Herceptin and docetaxel in its Marketing Authorisation indication is substantial.

Clinical Added Value

moderate

PERJETA in combination with trastuzumab and docetaxel provides a moderate improvement in actual benefit (level III) in the management of HER2-positive metastatic or locally recurrent unresectable breast cancer which has not previously been treated with anti-HER2 therapy or chemo‑therapy for the metastatic disease.

Therapeutic use

-